| Jane M Chandley, NP | |
|
20 Green Meadow Dr, Narragansett, RI 02882-5513 | |
| (401) 556-4211 | |
| Not Available |
| Full Name | Jane M Chandley |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 20 Green Meadow Dr, Narragansett, Rhode Island |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255509212 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | APRN01213 (Rhode Island) | Primary |
| 163WN0002X | Registered Nurse - Neonatal Intensive Care | CAPRN01213 (Rhode Island) | Secondary |
| Entity Name | Newport Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063632180 PECOS PAC ID: 0042111437 Enrollment ID: O20040422000696 |
News Archive
Cancer researchers at Georgetown University Medical Center have taken a step towards understanding how and why a widely used chemotherapy drug works in patients with breast cancer.
During a Dec. 8 press conference about Operation Warp Speed, President Donald Trump likened the spread of the coronavirus throughout the population — which experts agree bestows some immunity on the people who became ill — to having a COVID-19 vaccine.
Presidio Pharmaceuticals, Inc. announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the initiation of a Phase 1 first-in-human clinical trial of PPI-461, an orally administered NS5A inhibitor for the treatment of hepatitis C virus (HCV). The Phase 1 clinical trial will be conducted in healthy volunteers.
Inflammation is a balanced physiological response - the body needs it to eliminate invasive organisms and foreign irritants, but excessive inflammation can harm healthy cells, contributing to aging and chronic diseases.
› Verified 8 days ago
| Entity Name | Silver Spring Health Care Management Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861561193 PECOS PAC ID: 4688661127 Enrollment ID: O20080124000678 |
News Archive
Cancer researchers at Georgetown University Medical Center have taken a step towards understanding how and why a widely used chemotherapy drug works in patients with breast cancer.
During a Dec. 8 press conference about Operation Warp Speed, President Donald Trump likened the spread of the coronavirus throughout the population — which experts agree bestows some immunity on the people who became ill — to having a COVID-19 vaccine.
Presidio Pharmaceuticals, Inc. announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the initiation of a Phase 1 first-in-human clinical trial of PPI-461, an orally administered NS5A inhibitor for the treatment of hepatitis C virus (HCV). The Phase 1 clinical trial will be conducted in healthy volunteers.
Inflammation is a balanced physiological response - the body needs it to eliminate invasive organisms and foreign irritants, but excessive inflammation can harm healthy cells, contributing to aging and chronic diseases.
› Verified 8 days ago
| Entity Name | Affinity Physicians Llc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184944662 PECOS PAC ID: 0244413391 Enrollment ID: O20110326000053 |
News Archive
Cancer researchers at Georgetown University Medical Center have taken a step towards understanding how and why a widely used chemotherapy drug works in patients with breast cancer.
During a Dec. 8 press conference about Operation Warp Speed, President Donald Trump likened the spread of the coronavirus throughout the population — which experts agree bestows some immunity on the people who became ill — to having a COVID-19 vaccine.
Presidio Pharmaceuticals, Inc. announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the initiation of a Phase 1 first-in-human clinical trial of PPI-461, an orally administered NS5A inhibitor for the treatment of hepatitis C virus (HCV). The Phase 1 clinical trial will be conducted in healthy volunteers.
Inflammation is a balanced physiological response - the body needs it to eliminate invasive organisms and foreign irritants, but excessive inflammation can harm healthy cells, contributing to aging and chronic diseases.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jane M Chandley, NP 20 Green Meadow Dr, Narragansett, RI 02882-5513 Ph: (401) 556-4211 | Jane M Chandley, NP 20 Green Meadow Dr, Narragansett, RI 02882-5513 Ph: (401) 556-4211 |
News Archive
Cancer researchers at Georgetown University Medical Center have taken a step towards understanding how and why a widely used chemotherapy drug works in patients with breast cancer.
During a Dec. 8 press conference about Operation Warp Speed, President Donald Trump likened the spread of the coronavirus throughout the population — which experts agree bestows some immunity on the people who became ill — to having a COVID-19 vaccine.
Presidio Pharmaceuticals, Inc. announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the initiation of a Phase 1 first-in-human clinical trial of PPI-461, an orally administered NS5A inhibitor for the treatment of hepatitis C virus (HCV). The Phase 1 clinical trial will be conducted in healthy volunteers.
Inflammation is a balanced physiological response - the body needs it to eliminate invasive organisms and foreign irritants, but excessive inflammation can harm healthy cells, contributing to aging and chronic diseases.
› Verified 8 days ago